Skip to content

to study the effectiveness of ECT and tDCS in depression patients not responding to drugs

A comparative study to evaluate the efficacy of ECT and tDCS in treatment resistant depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/06/014545
Enrollment
60
Registered
2018-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features Health Condition 2: null- Treatment resistant depression

Interventions

Intervention1: Electro Convulsive Therapy: ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patien
cathode would be placed over the right DLPFC. The stimulation would be done with 2mA 20-minute twice daily sessions separated by atleast 3-hours for 5 days.

Sponsors

Ahana Hospitals LLP
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age range 18-60 years 2.Male and Female 3.Written informed consent. 4.Presence of Major Depressive Disorder as per DSM V guidelines 5.Refractory to at least two anti-depressant medications

Exclusion criteria

Exclusion criteria: 1. Co-morbid psychiatric diagnoses such as psychosis, bipolar disorder, substance dependence (including nicotine dependence) 2. Mental retardation, neurological disorders and severe medical illness 3. pregnancy or breast feeding 4.Diagnosis of major depressive disorder with psychotic features during the current depressive episode

Design outcomes

Primary

MeasureTime frame
Patient reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 2 weeks ] Response is defined as at least a 50% improvement in Baseline BDI score at End of Treatment Visit. The End of Treatment Visit will occur 2 weeks after the Baseline Visit Timepoint: Patient reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 2 weeks ] Response is defined as at least a 50% improvement in Baseline BDI score at End of Treatment Visit. The End of Treatment Visit will occur 2 weeks after the Baseline Visit

Secondary

MeasureTime frame
Clinician reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 2 weeks ] Number of patients with an improvement in their Baseline HAM-D score at the End of Treatment Visit. The End of Treatment Visit will occur 2 weeks after the Baseline Visit. Timepoint: Baseline and 2 weeks after the baseline visit

Countries

India

Contacts

Public ContactDrVikhram Ramasubramanian

Ahana Hospitals

vikharm@ahanahospitals.in9443772233

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026